Table 2.
Logistic regression analysis of the association of changes of endocan with the development of acute respiratory distress syndrome (ARDS) and septic shock
| Measure | Odds ratio | 95% CIs | p-value |
|---|---|---|---|
| Progression into ARDS | |||
| Any increase of endocan | 2.91 | 1.47–5.76 | 0.002 |
| Presence of at least one comorbiditya | 0.85 | 0.44–1.65 | 0.632 |
| Baseline SOFA score | 1.08 | 0.96–1.19 | 0.182 |
| Progression into septic shock | |||
| Any increase of endocan | 2.01 | 0.93–4.36 | 0.077 |
| Presence of at least one comorbiditya | 1.85 | 0.85–4.01 | 0.121 |
| Baseline SOFA score | 1.05 | 0.93–1.18 | 0.444 |
CI confidence interval, SOFA sequential organ failure assessment
aType 2 diabetes mellitus, chronic heart failure, chronic obstructive pulmonary disease, chronic renal disease, solid tumor malignancy, multiple injuries